Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Neurovance (Cambridge, MA), a clinical stage pharmaceutical company developing a norepinephrine, dopamine and serotonin triple uptake inhibitor to treat ADHD, closed a $7M Series A financing. Participants include Novartis Venture Fund and H&Q Life Sciences Investors.

Neurovance (Cambridge, MA), a clinical-stage pharmaceutical company focused on treatments for CNS disorders such as adult attention deficit hyperactivity disorder, closed a $7M Series A financing. Participants include Novartis Venture Fund. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP […]

BioBehavioral Diagnostics (Westford, MA) a commercial-stage diagnostics company focused on the Quotient™ ADHD System for the objective and accurate assessment of attention-deficit hyperactivity disorder, closed a $10M Series B financing. Participants include Sevin Rosen Funds and Tullis Health Investors.

Curemark (Rye, NY) a clinical-stage biopharma company focused on the treatment of neurological disease (autism and ADHD), clased a $6.5M Series A financing. Participants were not disclosed.

BioBehavioral Diagnostics (Cambridge, MA) a developer of a diagnostic system for measuring the core components of Attention Deficit Hyperactivity Disorder closed a $8.5M Series A financing. The deal was led by Sevin Rosen Funds and Tullis-Dickerson.

  

to top of page...